Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 2000 March;44(1) > The Quarterly Journal of Nuclear Medicine 2000 March;44(1):22-41

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

  NEUROENDOCRINE TUMORS
Guest Editors: Bombardieri E.


The Quarterly Journal of Nuclear Medicine 2000 March;44(1):22-41

language: English

Laboratory tests for neuroendocrine tumours

Seregni E., Ferrari L., Stivanello M. *, Dogliotti L. *

From the Nuclear Medicine Division Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
*Division of Medical Oncology University of Turin at San Luigi Hospital, Orbassano, Turin


FULL TEXT  


Neuroendocrine ­tumours (NETs) ­often ­have a ­good prog­no­sis and ­have pecu­liar bio­log­i­cal char­ac­ter­is­tics, ­among ­which the abil­ity to pro­duce and ­release bio­log­i­cal­ly ­active sub­stanc­es. Hypersecretion of hor­mones, bio­gen­ic ­amines or ­growth fac­tors ­often ­cause ­severe syn­dromes ­that are ­very debil­i­tat­ing. Now sen­si­tive ­assays for the meas­ure­ment of ­these sub­stanc­es ­have ­been devel­oped and ­this has ­improved the pos­sibil­ity of ­patient fol­low-up by ­means of in ­vitro exam­ina­tions. The deci­sion ­about ­which in ­vitro exam­ina­tion to be util­ised for NET man­age­ment is ­very dif­fi­cult ­because of the NET low inci­dence, the ­very ­large num­ber of mea­sur­able hor­mones, the dif­fi­cul­ty or low ­patient com­pli­ance for ­some diag­nos­tic ­tests. In ­this ­review we ­describe the ­most use­ful labor­a­to­ry ­tests for deter­min­ing the diag­no­sis of NET, ­their prog­nos­tic sig­nif­i­cance and the clin­i­cal val­ue of spe­cif­ic mark­er eval­u­a­tion in the fol­low-up of the NET ­patient. Particular con­sid­er­a­tion has ­been giv­en to bio­mark­ers for gas­troen­te­rop­an­creat­ic and sym­pa­tho-adren­al ­system ­tumours and for pros­tate and ­breast can­cers ­with neu­ro­en­do­crine dif­fe­ren­ti­a­tion.

top of page

Publication History

Cite this article as

Corresponding author e-mail